Corcept Therapeutics

Corcept reports a massive jump in profit and an increase in revenue on record trading volume, prompting management to sharply raise its full-year forecast. The new oncology drug Lifyorli is expected to deliver further growth in the medium term. Management is targeting annual sales of up to $5 billion by 2030. » Więcej na finanzen.net

The stock of Corcept Therapeutics rose to an all-time high of $122.50 and is currently trading at $121.31, corresponding to a market capitalization of $13.13 billion. In the second quarter of 2026 the company reported revenue of $256.1 million (+32% year-on-year) and raised its full-year guidance to $1.1–1.2 billion. Analysts responded with price-target increases and positive assessments, while InvestingPro currently rates the stock as overvalued relative to its fair value. » Więcej na de.investing.com

Shares of Corcept Therapeutics rose to a 52-week high of $95.18, gaining 152% over the past six months and 163% year-to-date. The company has resubmitted the New-Drug-Application for Relacorilant to the FDA for the treatment of Cushing’s syndrome; the review is expected to take six months. At ASCO, Corcept presented data from the phase‑3 ROSELLA study showing a 35% reduction in risk of death with Lifyorli (Relacorilant) plus nab‑paclitaxel. First-quarter 2026 revenues of about $165 million were below consensus, but analysts still raised price targets and reiterated buy ratings. » Więcej na de.investing.com